Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beacon Makes £96m Debut With Gene Therapy Pipeline For Unmet Retinal Needs

Backed By Syncona

Executive Summary

The UK firm’s substantial series A raise will help it advance a pipeline of gene therapy candidates for both rare and common retinal conditions, including a Phase II candidate rescued from a struggling biotech.

You may also be interested in...



Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal

Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche. 

Is Beacon Therapeutics A Future Phoenix From The Ashes Story?

With a platform of interesting preclinical assets and a Phase III-ready program from a collapsed biotech business, new company Beacon Therapeutics can claim unconventional origins. 

Aldeyra Thinks It May Have Broadly Applicable Retinitis Pigmentosa Therapy

Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel